Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from _______ to _______ Commission File Number 001-40440 _________________________ Senti Biosciences, Inc. (Exact name of registrant as specified in it ...

Table of Contents Senti Biosciences, Inc. (Exact name of registrant as specified in its charter) _________________________ (State or other jurisdiction of incorporation or organization) Delaware 86-2437900 (I.R.S. Employer Identification Number) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from _______ to _______ Commission File Number 001-40440 _________________________ Senti Biosciences, Inc. (Exact name of registrant as specified in its ch ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from _______ to _______ Commission File Number 001-40440 _________________________ Senti Biosciences, Inc. (Exact name of registrant as specified in it ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from _______ to _______ Commission File Number 001-40440 _________________________ Senti Biosciences, Inc. (Exact name of registrant as specified in it ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Commission File Number 001-40440 _________________________ Senti Biosciences, Inc. (Exact name of registrant as specified in its charter) _________________________ (State or other jurisdiction of incorporation or organization) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR ...

Financial Performance - For the three months ended March 31, 2022, the company reported a net loss of $1,309,849, primarily due to professional fees and other expenses of $1,282,742[123]. - The company incurred net cash used in operating activities of $492,630 for the three months ended March 31, 2022, mainly due to the net loss[126]. Initial Public Offering - The company generated gross proceeds of $230,000,000 from its Initial Public Offering of 23,000,000 shares at $10.00 per share[124]. - The underwriter received a cash underwriting fee of $0.20 per share, totaling $4,600,000 upon the closing of the Initial Public Offering[133]. - The company’s sponsor purchased 715,500 shares of Class A Common Stock at $10.00 per share, generating gross proceeds of $7,155,000[125]. Business Combination - The company entered into a Business Combination Agreement with Senti, with the merger expected to result in Senti becoming a wholly-owned subsidiary[119]. - The company plans to use substantially all funds held in the Trust Account to complete the initial business combination with Senti, including any interest earned[128]. - The company expects to incur significant costs in pursuing its initial business combination, including expenses related to due diligence and legal compliance[122]. Cash Position - As of March 31, 2022, the company had cash of $396,693 held outside the Trust Account, intended for completing the proposed initial business combination with Senti[127]. - The company has no off-balance sheet arrangements as of March 31, 2022[131].

(Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Commission File Number 001-40440 DYNAMICS SPECIAL PURPOSE CORP. (Exact name of registrant as specified in its charter) De ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) (Exact name of registrant as specified in its charter) Delaware 86-2437900 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40440 DYNAMICS SPECIAL PURPOSE CORP. (Exact name of registrant as specified in its charter) Delaware 8 ...